國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Biobettersprotein engineering to app...

Demeule, Barthelemy.

Biobettersprotein engineering to approach the curative /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Biobettersedited by Amy Rosenberg, Barthelemy Demeule.
其他題名:	protein engineering to approach the curative /
其他作者:	Rosenberg, Amy.
出版者:	New York, NY :Springer New York :2015.
面頁冊數:	xv, 378 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Protein engineering.
電子資源:	http://dx.doi.org/10.1007/978-1-4939-2543-8
ISBN:	9781493925438$q(electronic bk.)

Biobettersprotein engineering to approach the curative /
Biobettersprotein engineering to approach the curative /[electronic resource] :edited by Amy Rosenberg, Barthelemy Demeule. - New York, NY :Springer New York :2015. - xv, 378 p. :ill., digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,192210-7371 ;. - AAPS advances in the pharmaceutical sciences series ;3..

Introduction -- Targeting glucocerebrosidase to macrophages for effective treatment of patients with Gaucher disease: setting the paradigm of a "fit for purpose" approach to enzyme replacement therapy -- Challenges of Enzyme Replacement Therapy: Poor tissue distribution in lysosomal diseases using Pompe disease as a model -- Muscle targeting -- Blood-Brain Barrier Targeting of Therapeutic Lysosomal Enzymes -- Novel Methods for Addressing Immunogenicity in Therapeutic Enzymes -- Structure of monoclonal antibodies -- Prediction of aggregation in vivo by studies of therapeutic proteins in human plasma -- Effect of Hydrolytic Degradation on the In Vivo Properties of Monoclonal Antibodies -- Oxidation of proteins in the in-vivo environment: what we know; what we need to study and potential mitigation strategies -- Molecular assessment: balancing affinity, PK and manufacturability -- Perspectives on engineering biobetter therapeutic proteins with greater stability in inflammatory environments -- Antibody-like molecules designed for superior targeting and pharmacokinetics -- Alternative protein scaffolds as novel biotherapeutics -- Current strategies for pharmacokinetic optimization -- Biosimilar and Biobetter Scenarios for the US and Europe: What Should We Expect? -- Regulatory considerations for approval of biobetter products.

Over the last few decades, biopharmaceuticals have transformed many areas of healthcare and have given hope and extended the lives of many patients. Curative treatments, however, remain elusive in most cases. This book describes strategies to develop improved versions of biopharmaceuticals ("biobetters") to bridge the gap between existing therapies and curative therapies. With an aim to stimulate research and development in a wide array of therapeutic areas, diverse topics are covered, including the following: tissue specific targeting of enzyme replacement therapies; the development of novel protein structures with the potential to improve upon critical attributes of current monoclonal antibodies; the modification of current monoclonal antibody designs to improve their in vivo stability; and finally, the economic and regulatory considerations for the development of biobetters.

ISBN: 9781493925438$q(electronic bk.)

Standard No.: 10.1007/978-1-4939-2543-8doiSubjects--Topical Terms:

193722
Protein engineering.

LC Class. No.: TP248.65.P76

Dewey Class. No.: 660.63

Biobettersprotein engineering to approach the curative /
LDR:03303nmm a2200325 a 4500 001 474891
003 DE-He213
005 20160301105806.0
006 m d
007 cr nn 008maaau
008 160420s2015 nyu s 0 eng d
020 $a 9781493925438$q(electronic bk.)
020 $a 9781493925421$q(paper)
024 7 $a 10.1007/978-1-4939-2543-8 $2 doi
035 $a 978-1-4939-2543-8
040 $a GP $c GP
041 0 $a eng
050 4 $a TP248.65.P76
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
082 0 4 $a 660.63 $2 23
090 $a TP248.65.P76 $b B615 2015
245 0 0 $a Biobetters $h [electronic resource] : $b protein engineering to approach the curative / $c edited by Amy Rosenberg, Barthelemy Demeule.
260 $a New York, NY : $b Springer New York : $b Imprint: Springer, $c 2015.
300 $a xv, 378 p. : $b ill., digital ; $c 24 cm.
490 1 $a AAPS advances in the pharmaceutical sciences series, $x 2210-7371 ; $v 19
505 0 $a Introduction -- Targeting glucocerebrosidase to macrophages for effective treatment of patients with Gaucher disease: setting the paradigm of a "fit for purpose" approach to enzyme replacement therapy -- Challenges of Enzyme Replacement Therapy: Poor tissue distribution in lysosomal diseases using Pompe disease as a model -- Muscle targeting -- Blood-Brain Barrier Targeting of Therapeutic Lysosomal Enzymes -- Novel Methods for Addressing Immunogenicity in Therapeutic Enzymes -- Structure of monoclonal antibodies -- Prediction of aggregation in vivo by studies of therapeutic proteins in human plasma -- Effect of Hydrolytic Degradation on the In Vivo Properties of Monoclonal Antibodies -- Oxidation of proteins in the in-vivo environment: what we know; what we need to study and potential mitigation strategies -- Molecular assessment: balancing affinity, PK and manufacturability -- Perspectives on engineering biobetter therapeutic proteins with greater stability in inflammatory environments -- Antibody-like molecules designed for superior targeting and pharmacokinetics -- Alternative protein scaffolds as novel biotherapeutics -- Current strategies for pharmacokinetic optimization -- Biosimilar and Biobetter Scenarios for the US and Europe: What Should We Expect? -- Regulatory considerations for approval of biobetter products.
520 $a Over the last few decades, biopharmaceuticals have transformed many areas of healthcare and have given hope and extended the lives of many patients. Curative treatments, however, remain elusive in most cases. This book describes strategies to develop improved versions of biopharmaceuticals ("biobetters") to bridge the gap between existing therapies and curative therapies. With an aim to stimulate research and development in a wide array of therapeutic areas, diverse topics are covered, including the following: tissue specific targeting of enzyme replacement therapies; the development of novel protein structures with the potential to improve upon critical attributes of current monoclonal antibodies; the modification of current monoclonal antibody designs to improve their in vivo stability; and finally, the economic and regulatory considerations for the development of biobetters.
650 0 $a Protein engineering. $3 193722
650 0 $a Proteins $x Biotechnology. $3 193782
650 0 $a Protein drugs. $3 201234
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Pharmaceutical Sciences/Technology. $3 338426
650 2 4 $a Biomedicine general. $3 273948
700 1 $a Rosenberg, Amy. $3 728921
700 1 $a Demeule, Barthelemy. $3 728922
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a AAPS advances in the pharmaceutical sciences series ; $v 3. $3 559046
856 4 0 $u http://dx.doi.org/10.1007/978-1-4939-2543-8
950 $a Biomedical and Life Sciences (Springer-11642)